. 2021 Jul 5;10(8):845–851. doi: 10.1530/EC-21-0140
This work is licensed under a Table 1.
Baseline characteristics of participants with and without severe PAD.
| Characteristic | No-severe PAD (n = 159) | Severe PAD (n = 122) |
|---|---|---|
| Male (%) | 106 (66.7) | 71 (58.2) |
| Age (years) | 66 (56–74) | 72 (66–80) |
| Smoking (%) | 56 (35.4) | 38 (31.1) |
| Alcohol use (%) | 49 (30.8) | 31 (25.4) |
| Diabetes duration (years) | 10 (6–17) | 10 (8–20) |
| Diabetic foot ulcer duration (days) | 20 (7–30) | 30 (10–60) |
| Severe DFUs (%) | 66 (41.5) | 58 (47.5) |
| Hypertension (%) | 84 (52.8) | 96 (78.7) |
| SBP (mmHg) | 141 ± 22 | 146 ± 21 |
| DBP (mmHg) | 75 ± 12 | 76 ± 11 |
| Creatinine (μmol/L) | 69 (58–91) | 77 (59–107) |
| eGFR (EPI) mL/min/1.73m2) | 88.9 (67.4–100.3) | 78.4 (50.3–94.5) |
| ALB (g/L) | 34.4 (30.1–37.7) | 34.9 (31.1–37.9) |
| Hb (g/L) | 119.5 (104.8–133.3) | 118.0 (105.5–128.0) |
| HbA1c (%) | 9.5 (7.7–11.3) | 9.0 (7.3–11.4) |
| TC (mmol/L) | 4.2 (3.3–4.9) | 4.11 (3.30–5.16) |
| TG (mmol/L) | 1.22 (0.88–1.78) | 1.33 (0.91–1.88) |
| HDL-C (mmol/L) | 0.95 (0.75–1.19) | 0.93 (0.75–1.10) |
| LDL-C (mmol/L) | 2.29 (1.76–2.95) | 2.37 (1.67–3.05) |
| DM therapy | ||
| OHA therapy (%) | 65 (40.9) | 58 (47.5) |
| Insulin therapy (%) | 46 (28.9) | 35 (28.7) |
| OHA and insulin therapy (%) | 34 (21.4) | 21 (17.2) |
| None or unclear (%) | 14 (8.8) | 8 (6.6) |
| QTc interval (ms) | 429 (407–445) | 438 (423–455) |
ALB, albumin; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; Hb, hemoglobin; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OHA, oral hypoglycemic agent; PAD, peripheral arterial disease; QTc, heart rate-corrected QT interval; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride.